Here are five key notes:
1. The agreement will expand the availability of IBSchek.
2. Clinicians will be able to order blood draws on patients for testing through Quest’s approximately 2,200 patient service centers and 4,000 phlebotomists in the United States.
3. Specimens will then be forwarded to Commonwealth’s clinical laboratory in Salem, Mass., for testing.
4. The IBSchek is a new laboratory-developed blood test designed to help physicians diagnose irritable bowel syndrome.
5. Commonwealth launched IBSchek in May 2015.
More articles on GI/endoscopy:
Olympus releases new version of SONICBEAT device, EndoChoice shares drop 7.61% & more – 4 GI/endoscopy company key notes
Startup to commercialize colonoscopy reporting technology from OHSU
ACG names 23 winners of colorectal cancer outreach award
